Cholangiocarcinoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) (→Region) |
|||
| (15 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Cholangiocarcinoma}} | ||
{{CMG}}; {{AE}} {{F.K}} {{PSK}} | {{CMG}}; {{AE}}{{F.K}} [mailto:fkahe@bidmc.harvard.edu], {{PSK}} | ||
==Overview== | ==Overview== | ||
The [[incidence]] of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States. The [[prevalence]] of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals. Patients of all age groups may develop cholangiocarcinoma. Cholangiocarcinoma is more common in males than in females. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States. | *The [[incidence]] of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States. | ||
*The highest annual incidences of cholangiocarcinoma is 5.5 cases per 100,000 people in Japan, and 7.3 cases per 100,000 people in Israel. | *The highest annual incidences of cholangiocarcinoma is 5.5 cases per 100,000 people in Japan, and 7.3 cases per 100,000 people in Israel.<ref name="pmid18773060">{{cite journal |vauthors=Khan SA, Toledano MB, Taylor-Robinson SD |title=Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma |journal=HPB (Oxford) |volume=10 |issue=2 |pages=77–82 |year=2008 |pmid=18773060 |pmc=2504381 |doi=10.1080/13651820801992641 |url=}}</ref> | ||
===Prevalence=== | ===Prevalence=== | ||
*The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals. | *The [[prevalence]] of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals. | ||
*The [[prevalence]] of cholangiocarcinoma in patients with [[primary sclerosing cholangitis]] may be as high as 30%, based on autopsy studies. | *The [[prevalence]] of cholangiocarcinoma in patients with [[primary sclerosing cholangitis]] may be as high as 30%, based on [[autopsy]] studies.<ref name="pmid18773060">{{cite journal |vauthors=Khan SA, Toledano MB, Taylor-Robinson SD |title=Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma |journal=HPB (Oxford) |volume=10 |issue=2 |pages=77–82 |year=2008 |pmid=18773060 |pmc=2504381 |doi=10.1080/13651820801992641 |url=}}</ref><ref name="pmid25966423">{{cite journal |vauthors=Bergquist A, von Seth E |title=Epidemiology of cholangiocarcinoma |journal=Best Pract Res Clin Gastroenterol |volume=29 |issue=2 |pages=221–32 |year=2015 |pmid=25966423 |doi=10.1016/j.bpg.2015.02.003 |url=}}</ref> | ||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
*The mortality rate for intrahepatic cholangiocarcinoma among men increased from 0.17 to 0.78 per 100,000 in period of 1975-1979 to 1993-1997. | *The mortality rate for [[intrahepatic cholangiocarcinoma]] among men increased from 0.17 to 0.78 per 100,000 in period of 1975-1979 to 1993-1997.<ref name="pmid17457168">{{cite journal |vauthors=DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD |title=Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution |journal=Ann. Surg. |volume=245 |issue=5 |pages=755–62 |year=2007 |pmid=17457168 |pmc=1877058 |doi=10.1097/01.sla.0000251366.62632.d3 |url=}}</ref> | ||
*The mortality rate for intrahepatic cholangiocarcinoma among women | *The mortality rate for [[intrahepatic cholangiocarcinoma]] among women, increased from 0.12 to 0.57 per 100,000 in period of 1975-1979 to 1993-1997. | ||
===Age=== | ===Age=== | ||
*Patients of all age groups may develop cholangiocarcinoma. | *Patients of all age groups may develop cholangiocarcinoma. | ||
*The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders. | *The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with [[bile duct]] cystic disorders.<ref name="Macias2014">{{cite journal|last1=Macias|first1=Rocio I. R.|title=Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives|journal=ISRN Hepatology|volume=2014|year=2014|pages=1–13|issn=2314-4041|doi=10.1155/2014/828074}}</ref> | ||
*Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years. | *[[Bile duct]] cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years. | ||
===Race=== | ===Race=== | ||
*Cholangiocarcinoma usually affects individuals of the American Indian, Alaska Natives and Asian and Pacific Islanders race. | *Cholangiocarcinoma usually affects individuals of the American Indian, Alaska Natives and Asian and Pacific Islanders race.<ref name="pmid17032404">{{cite journal |vauthors=McLean L, Patel T |title=Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States |journal=Liver Int. |volume=26 |issue=9 |pages=1047–53 |year=2006 |pmid=17032404 |doi=10.1111/j.1478-3231.2006.01350.x |url=}}</ref> | ||
===Gender=== | ===Gender=== | ||
*Cholangiocarcinoma is more common in males than in females. | *Cholangiocarcinoma is more common in males than in females.<ref name="radio">Cholangiocarcinoma. Radiopaedia. http://radiopaedia.org/articles/cholangiocarcinoma</ref> | ||
===Region=== | ===Region=== | ||
*The majority of cholangiocarcinoma cases are reported in North America, Asia, and Australia. | *The majority of cholangiocarcinoma cases are reported in North America, Asia, and Australia.<ref name="pmid17032404">{{cite journal |vauthors=McLean L, Patel T |title=Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States |journal=Liver Int. |volume=26 |issue=9 |pages=1047–53 |year=2006 |pmid=17032404 |doi=10.1111/j.1478-3231.2006.01350.x |url=}}</ref> | ||
=== | |||
=== | |||
==References== | ==References== | ||
Latest revision as of 15:17, 12 February 2018
|
Cholangiocarcinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cholangiocarcinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Cholangiocarcinoma epidemiology and demographics |
|
Cholangiocarcinoma epidemiology and demographics in the news |
|
Risk calculators and risk factors for Cholangiocarcinoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2] [3], Suveenkrishna Pothuru, M.B,B.S. [4]
Overview
The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States. The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals. Patients of all age groups may develop cholangiocarcinoma. Cholangiocarcinoma is more common in males than in females.
Epidemiology and Demographics
Incidence
- The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States.
- The highest annual incidences of cholangiocarcinoma is 5.5 cases per 100,000 people in Japan, and 7.3 cases per 100,000 people in Israel.[1]
Prevalence
- The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals.
- The prevalence of cholangiocarcinoma in patients with primary sclerosing cholangitis may be as high as 30%, based on autopsy studies.[1][2]
Case-fatality rate/Mortality rate
- The mortality rate for intrahepatic cholangiocarcinoma among men increased from 0.17 to 0.78 per 100,000 in period of 1975-1979 to 1993-1997.[3]
- The mortality rate for intrahepatic cholangiocarcinoma among women, increased from 0.12 to 0.57 per 100,000 in period of 1975-1979 to 1993-1997.
Age
- Patients of all age groups may develop cholangiocarcinoma.
- The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders.[4]
- Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years.
Race
- Cholangiocarcinoma usually affects individuals of the American Indian, Alaska Natives and Asian and Pacific Islanders race.[5]
Gender
- Cholangiocarcinoma is more common in males than in females.[6]
Region
- The majority of cholangiocarcinoma cases are reported in North America, Asia, and Australia.[5]
References
- ↑ 1.0 1.1 Khan SA, Toledano MB, Taylor-Robinson SD (2008). "Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma". HPB (Oxford). 10 (2): 77–82. doi:10.1080/13651820801992641. PMC 2504381. PMID 18773060.
- ↑ Bergquist A, von Seth E (2015). "Epidemiology of cholangiocarcinoma". Best Pract Res Clin Gastroenterol. 29 (2): 221–32. doi:10.1016/j.bpg.2015.02.003. PMID 25966423.
- ↑ DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD (2007). "Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution". Ann. Surg. 245 (5): 755–62. doi:10.1097/01.sla.0000251366.62632.d3. PMC 1877058. PMID 17457168.
- ↑ Macias, Rocio I. R. (2014). "Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives". ISRN Hepatology. 2014: 1–13. doi:10.1155/2014/828074. ISSN 2314-4041.
- ↑ 5.0 5.1 McLean L, Patel T (2006). "Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States". Liver Int. 26 (9): 1047–53. doi:10.1111/j.1478-3231.2006.01350.x. PMID 17032404.
- ↑ Cholangiocarcinoma. Radiopaedia. http://radiopaedia.org/articles/cholangiocarcinoma